Ellen Heurlin stood in a Stockholm research lab with evidence of a breakthrough: when radiotherapy is paired with immunotherapy, advanced melanoma — the deadliest form of skin cancer — begins to shrink in ways that weren't possible with either treatment alone. Her doctoral research at Karolinska Institutet reveals that this combination doesn't just attack the irradiated tumors; in some patients, untreated metastases also decrease in size, a phenomenon suggesting the immune system awakens and hunts down cancer cells far beyond the treatment zone.
This matters because melanoma, for all its rarity compared to other cancers, is aggressively difficult to treat once it spreads. Patients facing advanced stages have few good options, and finding ways to improve outcomes without triggering severe side effects could reshape how oncologists approach the disease. Heurlin's thesis, which she will defend on June 12, maps a clearer path forward by combining old and new medical strategies in ways that actually work.
The evidence is striking. Patients receiving radiotherapy alongside immunotherapy often showed marked tumor shrinkage at the irradiated site. More intriguingly, some experienced what researchers call an abscopal effect — metastases that were never directly irradiated still declined in size, suggesting immunotherapy's reach extended far beyond the radiation beam. The treatment was well tolerated, with few serious side effects reported.
Heurlin also examined stereotactic radiotherapy, a precise form of radiation targeting small tumor areas, in patients with limited metastatic disease. The results showed excellent local tumor control and minimal toxicity, though no single patient group emerged as particularly exceptional beneficiaries. When immunotherapy exposure was analyzed, it didn't significantly change how long patients lived without disease progression or how many side effects they faced — but overall survival improved, a meaningful distinction that speaks to the quality of extra time gained.
The research extended to another patient group: those whose melanomas had begun resisting BRAF/MEK inhibitors, a class of targeted drugs that had previously kept their cancer at bay. In roughly half of these patients, adding radiotherapy provided clinical benefit. The treatment was tolerated well with no serious adverse effects, and continuing or switching systemic therapy proved better than stopping treatment altogether, even when progression was evident. This finding challenges the instinct to abandon a failing regimen entirely.
What makes this research valuable is not just the survival data but its practical implications for real patients. Heurlin's work suggests a new framework for combining radiotherapy with modern drug treatments — immunotherapy and targeted inhibitors alike — that could help oncologists decide when and how to deploy radiation alongside systemic therapy. The hope is that wider adoption of these insights will extend survival and quality of life for melanoma patients without adding unnecessary toxicity.
Looking ahead, Heurlin plans to compare outcomes between patients who received combined radiotherapy and systemic therapy versus those treated with systemic therapy alone. She also wants to explore radiotherapy in an adjuvant setting — after surgery — and investigate its role against melanoma brain metastases when combined with modern treatments. Beyond melanoma, she sees opportunities to illuminate the understudied role of radiotherapy in rarer skin cancers like Merkel cell carcinoma, basal cell carcinoma, and squamous cell carcinoma.